Holen Sie sich die Stockscreener-App
1.26
0.80%
0.01
Handel nachbörslich:
1.28
0.02
+1.59%
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
73,822
Relative Volume:
0.04
Marktkapitalisierung:
$5.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.56M
KGV:
-0.2389
EPS:
-5.274
Netto-Cashflow:
$-7.76M
1W Leistung:
-1.56%
1M Leistung:
+5.88%
6M Leistung:
-70.83%
1J Leistung:
-83.82%
1-Tages-Spanne:
$1.215
$1.30
1-Wochen-Bereich:
$1.20
$1.333
52-Wochen-Spanne:
$1.10
$9.899
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.26 | 5.03M | 0 | -7.56M | -7.76M | -5.274 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
Patterns Watch: Does LogProstyle Inc have strong fundamentalsDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
Sentiment Watch: Will Dermata Therapeutics Inc Equity Warrant outperform the market in YEARWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
WSBCO Should I Buy - Intellectia AI
Bond Watch: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Moving Averages: Is Dermata Therapeutics Inc Equity Warrant gaining market share2026 Institutional & Verified Technical Signals - baoquankhu1.vn
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Review: Will Dermata Therapeutics Inc benefit from AI trendsEntry Point & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sectors: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsTrade Exit Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Targets Report: Is Dermata Therapeutics Inc Equity Warrant stock undervalued right nowWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Gap Down: Will Bukit Jalil Global Acquisition 1 Ltd Equity Warrant benefit from green energy policies2026 Trends & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Whats the outlook for Dermata Therapeutics Incs sector2026 Price Targets & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
[PRE 14A] Dermata Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Market Moves: Can Dermata Therapeutics Inc Equity Warrant weather a recessionRate Hike & Smart Investment Allocation Insights - baoquankhu1.vn
CAS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALYAF Should I Buy - Intellectia AI
DRMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Dermata shares rise after USPTO issues patent notice of allowance - MSN
DRMA Should I Buy - Intellectia AI
Dermata receives Australian patent acceptance for topical filler - Investing.com Australia
01171 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dermata Therapeutics Receives Australian Patent Acceptance for Bioneedle Dermal Filler Delivery System - geneonline.com
Dermata receives Australian patent acceptance for topical filler By Investing.com - Investing.com Canada
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System - The Batesville Daily Guard
Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan
Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
TCFP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Guidance Update: Will Dermata Therapeutics Inc Equity Warrant benefit from AI trendsMarket Sentiment Report & Verified Short-Term Plans - baoquankhu1.vn
Tangible book value per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Total debt per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView — Track All Markets
Aug Levels: Will Dermata Therapeutics Inc benefit from seasonality2026 Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Quarterly Trades: Is Dermata Therapeutics Inc stock forming a cup and handleQuarterly Portfolio Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Dermata Therapeutics Reports Increased Losses in FY Earnings - Intellectia AI
Dermata Therapeutics 2025 Financial Update - AlphaStreet
Dermata Therapeutics Inc stock rises amid market gains - Intellectia AI
Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected - news.alphastreet.com
Dermata Therapeutics Announces Strategic Pivot to DTC Skincare with Tome Brand and Plans 2026 Product Launch - Minichart
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Bitget
Dermata Therapeutics 10-K: $7.56M net loss, operating expenses $7.77M - TradingView
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Dermata Therapeutics (NASDAQ: DRMA) pivots from Rx acne to Tome OTC skincare - Stock Titan
Dermata (NASDAQ: DRMA) shifts to DTC skincare as 2025 loss shrinks - Stock Titan
From prescription acne to at-home skincare: Dermata targets 2026 launch - Stock Titan
Analyst Downgrade: Will Dermata Therapeutics Inc benefit from AI trendsLong Setup & Precise Swing Trade Alerts - baoquankhu1.vn
Dermata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Risk Recap: Is Dermata Therapeutics Inc Equity Warrant a strong candidate for buy and hold2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates - news.alphastreet.com
If You Invested $1,000 in Protagenic Therapeutics Inc (PTIX) - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Valuation Update: Is Dermata Therapeutics Inc. Equity Warrant stock risky to hold now2026 Summary & Safe Entry Point Identification - baoquankhu1.vn
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):